TD Cowen analyst Charles Rhyee raised CVS Health's price target to $80, rating it a Buy with a potential upside of +40%. The firm sees 2025 as a turnaround year due to successful bid process and benefits redesign.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing